Unzyme Laboratories officially opens UPG Epsilon, our newest proving ground facility located in Helsinki, Finland. This state-of-the-art research center represents a significant expansion of our pharmaceutical enhancement testing capabilities and strengthens our presence in the Nordic region.
A New Era of Research Infrastructure
UPG Epsilon occupies a purpose-built 12,000 square meter facility in Helsinki’s Tiedepuisto science district, just minutes from our global headquarters. The location enables unprecedented integration between research operations and strategic leadership while providing participants with convenient access to cutting-edge clinical trials.
“UPG Epsilon represents our commitment to world-class research infrastructure,” said Erik Lindqvist, CEO. “As our product pipeline expands, so must our capacity to rigorously evaluate new technologies. This facility ensures we can accelerate development without compromising our exacting standards.”
Facility Capabilities
UPG Epsilon specializes in pharmaceutical enhancement testing, complementing the neural and cardiovascular focus of our other proving grounds:
- 200-bed residential research unit for extended study protocols
- Advanced bioanalytical laboratories with real-time monitoring capabilities
- Specialized facilities for metabolic, hematological, and immunological studies
- Integration with Helsinki University Hospital for comprehensive participant care
The facility is designed for both early-stage proof-of-concept studies and large-scale Phase III trials, providing flexibility across our development pipeline.
Research Programs
Initial research programs at UPG Epsilon will focus on:
- Next-generation HaemoFlow formulations
- Novel pharmaceutical enhancement compounds
- Combination therapies integrating multiple enhancement modalities
- Long-term safety surveillance for approved products
We anticipate enrolling the first participants in February 2024, with multiple studies launching throughout the year.
Community Integration
UPG Epsilon is designed to serve as a positive presence in the Helsinki community. We have established partnerships with local universities, created research internship programs, and committed to prioritizing local hiring for facility operations.
Our community engagement office welcomes inquiries from neighbors, civic organizations, and anyone interested in learning more about our work.
Join Our Research
Clinical trial participation at UPG Epsilon offers qualified volunteers the opportunity to contribute to advancing human enhancement while receiving comprehensive health monitoring and compensation. Current and upcoming studies are listed on our trials page.
The future of pharmaceutical enhancement begins here.